Skip to main content
Top
Published in: Pathology & Oncology Research 2/2010

01-06-2010

Pim-2 Activates API-5 to Inhibit the Apoptosis of Hepatocellular Carcinoma Cells Through NF-κB Pathway

Authors: Ke Ren, Wei Zhang, Yujun Shi, Jianping Gong

Published in: Pathology & Oncology Research | Issue 2/2010

Login to get access

Abstract

Pim-2 is proved to be relevant to the tumorigenesis of hepatocellular carcinoma (HCC), but the mechanism is unclear. We studied the relationship among Pim-2, NF-κB and API-5. In our experiment, expression level of the three factors and phosphorylation level of API-5, as well as NF-κB activity, were detected in HCC tissues and the nontumorous controls. Then Pim-2 gene was transfected into nontumorous liver cells L02, and Pim-2 SiRNA was transfected into hepatoblastoma cell line HepG2. Parthenolide was added as NF-κB inhibitor. The same detections as above were repeated in the cells, along with the apoptosis analysis. We found the levels of Pim-2, NF-κB and API-5, as well as NF-κB activity, were significantly higher in HCC tissues. Pim-2 level was increased in L02 cells after the transfection of Pim-2 gene, but decreased in HepG2 cells after the transfection of Pim-2 SiRNA. The levels of NF-κB and API-5, as well as NF-κB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. Cell apoptosis rates were negatively correlated with API-5 phosphorylation level. Therefore, we infer that Pim-2 could activate API-5 to inhibit the apoptosis of liver cells, and NF-κB is the key regulator.
Literature
1.
go back to reference Breuer ML, Cuypers HT, Berns A (1989) Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J 8(3):743–7488PubMed Breuer ML, Cuypers HT, Berns A (1989) Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J 8(3):743–7488PubMed
2.
go back to reference Ren K, Shi YJ, Gong JP (2007) The research on the mechanism of Pim-2 suppressing the apoptosis of tumor cell. Prog Physiol Sci 38(2):136–139 Ren K, Shi YJ, Gong JP (2007) The research on the mechanism of Pim-2 suppressing the apoptosis of tumor cell. Prog Physiol Sci 38(2):136–139
3.
go back to reference Chen JL, Limnander A, Rothman PB (2008) Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111(3):1677–1685CrossRefPubMed Chen JL, Limnander A, Rothman PB (2008) Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111(3):1677–1685CrossRefPubMed
4.
go back to reference Dai H, Li R, Wheeler T et al (2005) Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65(3):276–286CrossRefPubMed Dai H, Li R, Wheeler T et al (2005) Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65(3):276–286CrossRefPubMed
5.
go back to reference Gong J, Wang J, Ren K et al (2008) Serine/Threonine Kinase Pim-2 Promotes Liver Tumorigenesis Induction through Mediating Survival and Preventing Apoptosis of Liver Cell. J Surg Res. Apr 22. [Epub ahead of print] Gong J, Wang J, Ren K et al (2008) Serine/Threonine Kinase Pim-2 Promotes Liver Tumorigenesis Induction through Mediating Survival and Preventing Apoptosis of Liver Cell. J Surg Res. Apr 22. [Epub ahead of print]
6.
go back to reference Li B, Ye T, Li DH (2008) Expression of Pim-2 in normal liver and hepatocellular carcinoma tissues. Chinese J Hepatol 16(12):950–951 Li B, Ye T, Li DH (2008) Expression of Pim-2 in normal liver and hepatocellular carcinoma tissues. Chinese J Hepatol 16(12):950–951
7.
go back to reference Hammerman PS, Fox CJ, Cinalli RM et al (2004) Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation. Cancer Res 64:8341–8348CrossRefPubMed Hammerman PS, Fox CJ, Cinalli RM et al (2004) Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation. Cancer Res 64:8341–8348CrossRefPubMed
8.
go back to reference Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505–2511PubMed Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505–2511PubMed
9.
go back to reference White E (2003) The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev 17:1813–1816CrossRefPubMed White E (2003) The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev 17:1813–1816CrossRefPubMed
10.
go back to reference Macdonald A, Campbell DG, Toth R et al (2006) Pim kinases phosphorylate multiple sites on Bad and promote14–3–3 binding and dissociation from Bcl-XL. BMC Cell Biol 7:1186–1471CrossRef Macdonald A, Campbell DG, Toth R et al (2006) Pim kinases phosphorylate multiple sites on Bad and promote14–3–3 binding and dissociation from Bcl-XL. BMC Cell Biol 7:1186–1471CrossRef
11.
go back to reference Peng C, Knebel A, Morrice NA et al (2007) Pim kinase substrate identification and specificity. J Biochem 141(3):353–62CrossRefPubMed Peng C, Knebel A, Morrice NA et al (2007) Pim kinase substrate identification and specificity. J Biochem 141(3):353–62CrossRefPubMed
12.
go back to reference Wang Y, Lee AT, Ma JZ et al (2008) Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224 specific target. J Biol Chem 283(19):13205–15CrossRefPubMed Wang Y, Lee AT, Ma JZ et al (2008) Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224 specific target. J Biol Chem 283(19):13205–15CrossRefPubMed
13.
go back to reference Hehner SP, Hofmann TG, Dröge W et al (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163(10):5617–23PubMed Hehner SP, Hofmann TG, Dröge W et al (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163(10):5617–23PubMed
14.
go back to reference Li W, Lei P, Yu B et al (2008) Screening and identification of a novel target specific for hepatoma cell line HepG2 from the FliTrx bacterial peptide library. Acta Biochim Biophys Sin 40(5):443–51CrossRefPubMed Li W, Lei P, Yu B et al (2008) Screening and identification of a novel target specific for hepatoma cell line HepG2 from the FliTrx bacterial peptide library. Acta Biochim Biophys Sin 40(5):443–51CrossRefPubMed
15.
go back to reference Guzman ML, Rossi RM, Karnischky L et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105(11):4163–9CrossRefPubMed Guzman ML, Rossi RM, Karnischky L et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105(11):4163–9CrossRefPubMed
16.
go back to reference Jiang JX, Mikami K, Venugopal S et al (2009) Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 51(1):139–48CrossRefPubMed Jiang JX, Mikami K, Venugopal S et al (2009) Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 51(1):139–48CrossRefPubMed
17.
go back to reference Hoffmann F, Sass G, Zillies J et al (2009) A novel technique for selective NF-kappaB inhibition in Kupffer cells - contrary effects in fulminant hepatitis and ischemia/reperfusion. Gut May 25. [Epub ahead of print] Hoffmann F, Sass G, Zillies J et al (2009) A novel technique for selective NF-kappaB inhibition in Kupffer cells - contrary effects in fulminant hepatitis and ischemia/reperfusion. Gut May 25. [Epub ahead of print]
18.
go back to reference Kuboki S, Sakai N, Clarke C et al (2009) The peptidyl-prolyl isomerase, Pin1, facilitates NF-kappaB binding in hepatocytes and protects against hepatic ischemia/reperfusion injury. J Hepatol May 24. [Epub ahead of print] Kuboki S, Sakai N, Clarke C et al (2009) The peptidyl-prolyl isomerase, Pin1, facilitates NF-kappaB binding in hepatocytes and protects against hepatic ischemia/reperfusion injury. J Hepatol May 24. [Epub ahead of print]
19.
go back to reference Pelengaris S, Khan M, Evan G (2002) c-Myc: more than just a matter of life and death. Nature Reviews. Cancer 2(10):764–776PubMed Pelengaris S, Khan M, Evan G (2002) c-Myc: more than just a matter of life and death. Nature Reviews. Cancer 2(10):764–776PubMed
20.
go back to reference Hammerman PS, Fox CJ, Cinalli RM et al (2004) Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation. Cancer Res 64:8341–8348CrossRefPubMed Hammerman PS, Fox CJ, Cinalli RM et al (2004) Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation. Cancer Res 64:8341–8348CrossRefPubMed
21.
go back to reference Zhang Y, Wang Z, Li X et al (2008) Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27(35):4809–19CrossRefPubMed Zhang Y, Wang Z, Li X et al (2008) Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27(35):4809–19CrossRefPubMed
22.
23.
go back to reference Fujii C, Nakamoto Y, Lu P et al (2005) Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 114(2):209–218CrossRefPubMed Fujii C, Nakamoto Y, Lu P et al (2005) Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 114(2):209–218CrossRefPubMed
24.
go back to reference Qian K, Wang L, Cywin CL et al (2009) Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 52(7):1814–27CrossRefPubMed Qian K, Wang L, Cywin CL et al (2009) Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 52(7):1814–27CrossRefPubMed
25.
go back to reference Xia Z, Knaak C, Ma J et al (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52(1):74–86CrossRefPubMed Xia Z, Knaak C, Ma J et al (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52(1):74–86CrossRefPubMed
26.
go back to reference Tong Y, Stewart KD, Thomas S et al (2008) Isoxazolo [3, 4-b] quinoline-3, 4 (1H, 9H) -diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett 18(19):5206–5208CrossRefPubMed Tong Y, Stewart KD, Thomas S et al (2008) Isoxazolo [3, 4-b] quinoline-3, 4 (1H, 9H) -diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett 18(19):5206–5208CrossRefPubMed
Metadata
Title
Pim-2 Activates API-5 to Inhibit the Apoptosis of Hepatocellular Carcinoma Cells Through NF-κB Pathway
Authors
Ke Ren
Wei Zhang
Yujun Shi
Jianping Gong
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9215-4

Other articles of this Issue 2/2010

Pathology & Oncology Research 2/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine